These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 12607097)

  • 1. CpG immuno-stimulatory motifs enhance humoral immune responses against hepatitis C virus core protein after DNA-based immunization.
    Encke J; zu Putlitz J; Stremmel W; Wands JR
    Arch Virol; 2003 Mar; 148(3):435-48. PubMed ID: 12607097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic immunization of wild-type and hepatitis C virus transgenic mice reveals a hierarchy of cellular immune response and tolerance induction against hepatitis C virus structural proteins.
    Satoi J; Murata K; Lechmann M; Manickan E; Zhang Z; Wedemeyer H; Rehermann B; Liang TJ
    J Virol; 2001 Dec; 75(24):12121-7. PubMed ID: 11711603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine-expressing plasmids.
    Geissler M; Gesien A; Tokushige K; Wands JR
    J Immunol; 1997 Feb; 158(3):1231-7. PubMed ID: 9013964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Enhancement of cellular immune response to DNA vaccine encoding hepatitis C virus core and envelope 2 fusion antigen by murine Fms-like tyrosine kinase 3 ligand].
    Ke JS; Zhao P; Cao J; Yu JP; Qi ZT
    Sheng Wu Gong Cheng Xue Bao; 2003 Mar; 19(2):158-62. PubMed ID: 15966314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral immunization with attenuated Salmonella carrying a co-expression plasmid encoding the core and E2 proteins of hepatitis C virus capable of inducing cellular immune responses and neutralizing antibodies in mice.
    Cao J; Chen Z; Ren Y; Luo Y; Cao M; Lu W; Zhao P; Qi Z
    Vaccine; 2011 May; 29(20):3714-23. PubMed ID: 21396407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitory effects of chronic ethanol consumption on cellular immune responses to hepatitis C virus core protein are reversed by genetic immunizations augmented with cytokine-expressing plasmids.
    Geissler M; Gesien A; Wands JR
    J Immunol; 1997 Nov; 159(10):5107-13. PubMed ID: 9366440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vigorous hepatitis C virus-specific CD4+ and CD8+ T cell responses induced by protein immunization in the presence of Montanide ISA720 plus synthetic oligodeoxynucleotides containing immunostimulatory cytosine-guanine dinucleotide motifs.
    Sugauchi F; Wang RY; Qiu Q; Jin B; Alter HJ; Shih JW
    J Infect Dis; 2006 Feb; 193(4):563-72. PubMed ID: 16425136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a heterologous, multigenotype vaccine against hepatitis C virus infection.
    Encke J; Radunz W; Eisenbach C; Geib J; Gehrke S; Pfaff E; Stremmel W
    Eur J Clin Invest; 2007 May; 37(5):396-406. PubMed ID: 17461986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression and immune response to hepatitis C virus core DNA-based vaccine constructs.
    Tokushige K; Wakita T; Pachuk C; Moradpour D; Weiner DB; Zurawski VR; Wands JR
    Hepatology; 1996 Jul; 24(1):14-20. PubMed ID: 8707253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel combined vaccine candidate containing epitopes of HCV NS3, core and E1 proteins induces multi-specific immune responses in BALB/c mice.
    Zeng R; Li G; Ling S; Zhang H; Yao Z; Xiu B; He F; Huang R; Wei L
    Antiviral Res; 2009 Oct; 84(1):23-30. PubMed ID: 19646486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of conventional or replicating nucleic acid-based vaccines and recombinant Semliki forest virus-derived particles for the induction of immune responses against hepatitis C virus core and E2 antigens.
    Vidalin O; Fournillier A; Renard N; Chen M; Depla E; Boucreux D; Brinster C; Baumert T; Nakano I; Fukuda Y; Liljeström P; Trépo C; Inchauspé G
    Virology; 2000 Oct; 276(2):259-70. PubMed ID: 11040118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunization with hepatitis C virus-like particles induces humoral and cellular immune responses in nonhuman primates.
    Jeong SH; Qiao M; Nascimbeni M; Hu Z; Rehermann B; Murthy K; Liang TJ
    J Virol; 2004 Jul; 78(13):6995-7003. PubMed ID: 15194776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparison of immune responses induced by recombinant attenuated Salmonella typhi carrying eukaryotic expression plasmid or prokaryotic expression plasmid of HCV core protein].
    Chen ZH; Zhao P; Wu SM; Cao J; Zhang B; Wan MB; Ke JS; Qi ZT
    Sheng Wu Gong Cheng Xue Bao; 2007 Sep; 23(5):862-6. PubMed ID: 18051866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of immunization in mice with recombinant DNA encoding the hepatitis C virus structural protein.
    Dou J; Liu K; Chen Z; Wo J; He N; Liu Y; Zhang M; Wang X; Xu C
    Chin Med J (Engl); 1999 Nov; 112(11):1036-9. PubMed ID: 11721468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CpG ODN enhances immunization effects of hepatitis B vaccine in aged mice.
    Qin W; Jiang J; Chen Q; Yang N; Wang Y; Wei X; Ou R
    Cell Mol Immunol; 2004 Apr; 1(2):148-52. PubMed ID: 16212903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C virus (HCV) core protein enhances the immunogenicity of a co-delivered DNA vaccine encoding HCV structural antigens in mice.
    Alvarez-Lajonchere L; González M; Alvarez-Obregón JC; Guerra I; Viña A; Acosta-Rivero N; Musacchio A; Morales J; Dueñas-Carrera S
    Biotechnol Appl Biochem; 2006 Apr; 44(Pt 1):9-17. PubMed ID: 16367740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HCV-NS3 Th1 minigene vaccine based on invariant chain CLIP genetic substitution enhances CD4(+) Th1 cell responses in vivo.
    Gao M; Wang HP; Wang YN; Zhou Y; Wang QL
    Vaccine; 2006 Jun; 24(26):5491-7. PubMed ID: 16725235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial.
    Alvarez-Lajonchere L; Shoukry NH; Grá B; Amador-Cañizares Y; Helle F; Bédard N; Guerra I; Drouin C; Dubuisson J; González-Horta EE; Martínez G; Marante J; Cinza Z; Castellanos M; Dueñas-Carrera S
    J Viral Hepat; 2009 Mar; 16(3):156-67. PubMed ID: 19017255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fusion of HBsAg and prime/boosting augment Th1 and CTL responses to HCV polytope DNA vaccine.
    Memarnejadian A; Roohvand F
    Cell Immunol; 2010; 261(2):93-8. PubMed ID: 20056196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel hepatitis C virus vaccine approach using recombinant Bacillus Calmette-Guerin expressing multi-epitope antigen.
    Wei SH; Yin W; An QX; Lei YF; Hu XB; Yang J; Lu X; Zhang H; Xu ZK
    Arch Virol; 2008; 153(6):1021-9. PubMed ID: 18421415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.